Etoposide

  • 4'-Dimethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
  • EPEC
  • 9-((4,6-o-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4
  • Hydroxy-3,4-dimethyloxyphenyl)furo (3',4'':6,7)
  • Naptho-(2,3-D)-1,3-dioxol-6 (5ah)-one
  • Vepesid
Formula
C29H32O13
Structure
Description
Typically in the form of pink, liquid fillled, soft gelatin capsules.
Uses
Medication.

Registry Numbers and Inventories.
CAS
33419-42-0
EC (EINECS/ELINCS)
251-509-1
RTECS
KC0190000
RTECS class
Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data
Merck
12,3931
Beilstein/Gmelin
3659695
Austrailia AICS
Listed
New Zealand
Listed

Properties.
Formula
C29H32O13
Formula mass
588.57
Melting point, °C
262 - 263
Solubility in water
approx 0.08 mg/ml

Hazards and Protection.
Storage
Store under refrigeration, in orginal container.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Surgical latex gloves -- which should be changed regularly. Safety goggles.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Scoop up material and place in container for later disposal.
Stability
Stable under normal storage and usage conditions. Avoid elevated temperatures.

Fire.
Fire fighting
Wear SCBA and full protective clothing. Extinguish fire with water, COT or dry chemical powder.

Health.
Carcinogin
I-2A
Exposure effects
Bone marrow supression. Cytotoxic agent. Anaphlactic-like reaction is possible. Possible carcinogen.
   Ingestion
Ausea, vomiting and diarrhea commonly occur. Paralytic ileus has been reported.
   Inhalation
Dyspnea, acute bronchospasm, apnea and cyanosis have been reported. Fatal pulmonary toxicity has been reported after oral use.
   Skin
Rash, urticaria and/or pruritus have been infrequently reported. Erythema and desquamation, alopecia, onycholysis, and stevens-johnson syndrome have occurred following therapeutic use of etoposide.
   Eyes
Conjunctivitis.

First aid
 
   Ingestion
Seek immediate medial attention.
   Inhalation
Seek immediate medial attention.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility.

Transport.